Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5‐HT2A receptors in rats.

Autor: Amada, Naoki1 (AUTHOR) amada.naoki@otsuka.jp, Akazawa, Hitomi1 (AUTHOR), Ohgi, Yuta1 (AUTHOR), Maeda, Kenji2 (AUTHOR), Sugino, Haruhiko3 (AUTHOR), Kurahashi, Nobuyuki4 (AUTHOR), Kikuchi, Tetsuro5 (AUTHOR), Futamura, Takashi1 (AUTHOR)
Zdroj: Neuropsychopharmacology Reports. Dec2019, Vol. 39 Issue 4, p279-288. 10p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje